ReviewClinical kidney journal2017
Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions.
Review in Clinical kidney journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- The optimal exercise modality and intensity for hemodialysis patients incorporating Bayesian network meta-analysis and systematic review.Frontiers in physiology · 2022Pooled it
- Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review.Kidney diseases (Basel, Switzerland) · 2020Pooled it
- Association of Intravenous Versus Oral Iron Therapy With Clinical Outcomes in Patients With Advanced CKD.Kidney medicine · 2026Article
- Exploring the relationship between intravenous iron therapy and troponin T levels in hemodialysis patients: a cross-sectional study.BMC nephrology · 2025Article
- Impact of Intravenous Iron Replacement Therapy on Healthcare Costs for Patients with Iron Deficiency Anemia in the USA: A Retrospective Analysis.Drugs - real world outcomes · 2025Article
- A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron.Drug delivery and translational research · 2025Article
- Effect of Ferric Carboxymaltose Versus Low-Dose Intravenous Iron Therapy and Iron Sucrose on the Total Cost of Care in Patients with Iron Deficiency Anemia: A US Claims Database Analysis.Drugs - real world outcomes · 2024Article
- Cardiorenal syndrome and iron supplementation-more benefits than risks: a narrative review.International urology and nephrology · 2024Review
- Bone marrow macrophage iron content and sideroblast count in iron- and ESA-naïve patients with CKD-related anemia.Renal failure · 2023Article
- The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors.Clinical kidney journal · 2023Review
- Redefining both iron deficiency and anaemia in cardiovascular disease.European heart journal · 2023Article
- Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney.Nature reviews. Nephrology · 2023Review
- Ferroptosis as a Potential Therapeutic Target of Traditional Chinese Medicine for Mycotoxicosis: A Review.Toxics · 2023Review
- Management of anaemia in French dialysis patients: results from a large epidemiological retrospective study.Clinical kidney journal · 2023Article
- Article
- Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease.Frontiers in pediatrics · 2022Article
- Safety of Intravenous Iron in CKD Stage 3-5 Patients Not on Dialysis: A Retrospective Cohort Study.Canadian journal of kidney health and disease · 2022Article
- Article
- ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?Journal of clinical medicine · 2021Review
- Exercise intolerance in kidney diseases: physiological contributors and therapeutic strategies.American journal of physiology. Renal physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current recommendations for the use of intravenous iron therapy in the management of anaemia in patients with chronic kidney disease (CKD) are based on limited clinical evidence. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anaemia in Chronic Kidney Disease in 2012, a number of randomized clinical trials [notably, the Ferinject Assessment in Patients with Iron Deficiency Anaemia (FIND-CKD) and Randomized Trial to Evaluate IV and Oral Iron in Chronic Kidney Disease (REVOKE) trials] and observational studies have been completed, and a further large clinical trial-Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL)-is currently underway. In this article, the implications of the findings from these recent studies are discussed and the critical evidence gaps that remain to be addressed are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.